Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RGS2: a “turn-off” in hypertension
Thu H. Le, Thomas M. Coffman
Thu H. Le, Thomas M. Coffman
Published February 15, 2003
Citation Information: J Clin Invest. 2003;111(4):441-443. https://doi.org/10.1172/JCI17836.
View: Text | PDF
Commentary

RGS2: a “turn-off” in hypertension

  • Text
  • PDF
Abstract

Authors

Thu H. Le, Thomas M. Coffman

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Regulation of G protein signaling by RGS2. (a) During basal state the AT...
Regulation of G protein signaling by RGS2. (a) During basal state the AT1 receptor spans the cell membrane and is associated with a heterotrimeric G protein. (b) Binding of hormone (angiotensin II) activates the G protein–coupled AT1 receptor, causing a conformational change and exchange of GDP for GTP on Gαq. The Gαq-GTP and Gβγ subunits dissociate and are free to activate downstream effector proteins, which eventually results in physiological actions such as vasoconstriction and vascular smooth muscle cell (VSMC) hypertrophy. Ang II, angiotensin II. (c) In the presence of RGS proteins, such as RGS2, the Gαq-catalyzed hydrolysis of GTP to GDP is accelerated, terminating the Gα-effector interactions. The Gα-GDP complex has high affinity for the Gβγ subunit, and reassociation of the Gαβγ-GDP unit with the receptor returns the system to the basal state (a).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts